Anticanceragent 292 (Compound P4) is a photosensitizer targeting melanoma. It exhibits good biocompatibility in the absence of light and, when exposed to light, induces apoptosis and partial necrosis of B16-F10 cells by disrupting lysosomal membranes. Furthermore, Anticanceragent 292 not only directly kills tumor cells through generated ROS but also induces immunogenic cell death (ICD), leading to antitumor immune responses. This compound is applicable for research in photodynamic therapy for melanoma.